Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 14–15
HOS-114825 · Präparat HOS-094169
14
Antimalarial
Halofantrine Based on theoretical Due to their metabolic profile and
Lumefantrine considerations, tipranavir, co- inherent risk of inducing torsades
No interaction study administered with low dose de pointes, administration of
performed ritonavir, is expected to increase halofantrine and lumefantrine
halofantrine and lumefantrine with Aptivus, co-administered
concentrations. with low dose ritonavir, is not
recommended (see section 4.4).
Inhibition of CYP 3A4 by
tipranavir/r
Anticonvulsants
Carbamazepine 200 mg Carbamazepine total* Cmax ↑ 13% Carbamazepine should be used
BID Carbamazepine total* AUC ↑ with caution in combination with
16% Aptivus, co-administered with
Carbamazepine total* Cmin ↑ 23% low dose ritonavir. Higher doses
of carbamazepine (> 200 mg)
*Carbamazepine total = total of may result in even larger
carbamazepine and epoxy- decreases in tipranavir plasma
carbamazepine (both are concentrations (see section 4.4).
pharmacologically active
moieties).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) carbamazepine (HOS-085618) halofantrine (HOS-085606) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage d7ecbb0643db716f99683b06b82b0b19ce946076955e0bd9b9d32a14665c4920 · Zeichen 26398–28039 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 18
HOS-116382 · Präparat HOS-094447
Clotrimazole Not Studied. Concomitant systemic use
of clotrimazole and boosted PREZISTA
may increase plasma concentrations of
darunavir and/or clotrimazole.
darunavir AUC24h ↑ 33% (based on
population pharmacokinetic model)
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage
colchicine and boosted PREZISTA may or an interruption of colchicine
increase the exposure to colchicine. treatment is recommended in
(CYP3A and/ or P-gp inhibition) patients with normal renal or
hepatic function if treatment with
boosted PREZISTA is required.
For patients with renal or hepatic
impairment colchicine with
boosted PREZISTA is
contraindicated (see sections 4.3
and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of boosted
80/480 mg, 6 doses at 0, artemether Cmin ↔ PREZISTA and
8, 24, 36, 48, and artemether Cmax ↓ 18% artemether/lumefantrine can be
60 hours dihydroartemisinin AUC ↓ 18% used without dose adjustments;
dihydroartemisinin Cmin ↔ however, due to the increase in
dihydroartemisinin Cmax ↓ 18% lumefantrine exposure, the
lumefantrine AUC ↑ 175% combination should be used with
caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) clotrimazole (HOS-090574) colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage b3442ef6ceaf51a29429b2633afb31e8bf018bd31dee5803edca0ef04ffe7a51 · Zeichen 42404–44942 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-116524 · Präparat HOS-094447
59
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage
colchicine and darunavir co-administered or an interruption of colchicine
with low dose ritonavir may increase the treatment is recommended in
exposure to colchicine. patients with normal renal or
(CYP3A and/ or P-gp inhibition) hepatic function if treatment with
PREZISTA co-administered with
low dose ritonavir is required. For
patients with renal or hepatic
impairment colchicine with
PREZISTA co-administered with
low dose ritonavir is
contraindicated (see sections 4.3
and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of PREZISTA
80/480 mg, 6 doses at 0, artemether Cmin ↔ and artemether/lumefantrine can
8, 24, 36, 48, and artemether Cmax ↓ 18% be used without dose adjustments;
60 hours dihydroartemisinin AUC ↓ 18% however, due to the increase in
dihydroartemisinin Cmin ↔ lumefantrine exposure, the
dihydroartemisinin Cmax ↓ 18% combination should be used with
lumefantrine AUC ↑ 175% caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and
Rifapentine are strong CYP3A inducers and have PREZISTA with concomitant low
been shown to cause profound decreases dose ritonavir is not recommended.
in concentrations of other protease
inhibitors, which can result in virological The combination of rifampicin and
failure and resistance development PREZISTA with concomitant low
(CYP450 enzyme induction). During dose ritonavir is contraindicated
attempts to overcome the decreased (see section 4.3).
exposure by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) protease (HOS-085623) colchicine (HOS-086147) rifapentine (HOS-116386) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 74158b50c5b99095b0e72f07cfddcb7308a227dde01097c23cb4f0a091942901 · Zeichen 33301–36423 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 100
HOS-116614 · Präparat HOS-094447
Clotrimazole Not studied. Concomitant systemic use of
clotrimazole and boosted PREZISTA
may increase plasma concentrations of
darunavir and/or clotrimazole.
darunavir AUC24h ↑ 33% (based on
population pharmacokinetic model)
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage
colchicine and boosted PREZISTA may or an interruption of colchicine
increase the exposure to colchicine. treatment is recommended in
(CYP3A and/ or P-gp inhibition) patients with normal renal or
hepatic function if treatment with
boosted PREZISTA is required.
For patients with renal or hepatic
impairment colchicine with
boosted PREZISTA is
contraindicated (see sections 4.3
and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of boosted
80/480 mg, 6 doses at 0, artemether Cmin ↔ PREZISTA and
8, 24, 36, 48, and artemether Cmax ↓ 18% artemether/lumefantrine can be
60 hours dihydroartemisinin AUC ↓ 18% used without dose adjustments;
dihydroartemisinin Cmin ↔ however, due to the increase in
dihydroartemisinin Cmax ↓ 18% lumefantrine exposure, the
lumefantrine AUC ↑ 175% combination should be used with
caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) clotrimazole (HOS-090574) colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8320ed1d6a90756ad97ebcafad72b22fac708f30b38e3c755578b2bedaeadfbe · Zeichen 41875–44413 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-119740 · Präparat HOS-095005
11
ANTIMALARIALS
Artemether/ artemether Close monitoring of
Lumefantrine AUC ↓ 0.62 (0.48-0.80) antimalarial response is
80/480 mg, 6 doses at 0,
Cmin ↓ 0.82 (0.67-1.01) warranted when
8, 24, 36, 48, andCmax ↓ 0.72 (0.55-0.94) co-administering
60 hours dihydroartemisinin INTELENCE and
AUC ↓ 0.85 (0.75-0.97) artemether/lumefantrine as a
Cmin ↓ 0.83 (0.71-0.97) significant decrease in
Cmax ↓ 0.84 (0.71-0.99) exposure of artemether and
lumefantrine its active metabolite,
AUC ↓ 0.87 (0.77-0.98) dihydroartemisinin, may
Cmin ↔ 0.97 (0.83-1.15) result in decreased
Cmax ↔ 1.07 (0.94-1.23) antimalarial efficacy. No
etravirine dose adjustment is needed for
AUC ↔ 1.10 (1.06-1.15) INTELENCE.
Cmin ↔ 1.08 (1.04-1.14)
Cmax ↔ 1.11 (1.06-1.17)
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifampicin and rifapentine are Combination not
Rifapentine expected to decrease plasma concentrations of recommended.
etravirine.
INTELENCE should be used in combination
with a boosted PI. Rifampicin is contraindicated
in combination with boosted Pis.
Rifabutin With an associated boosted PI: The combination of
300 mg once daily No interaction study has been performed. Based INTELENCE with a boosted
on historical data, a decrease in etravirine PI and rifabutin should be
exposure may be expected whereas an increase used with caution due to the
in rifabutin exposure and especially in risk of decrease in etravirine
25-O-desacetyl-rifabutin may be expected. exposure and the risk of
increase in rifabutin and
With no associated boosted PI (out of the 25-O-desacetyl-rifabutin
recommended indication for etravirine): exposures.
rifabutin Close monitoring for
AUC ↓ 0.83 (0.75-0.94) virologic response and for
Cmin ↓ 0.76 (0.66-0.87) rifabutin related adverse
Cmax ↓ 0.90 (0.78-1.03) reactions is recommended.
25-O-desacetyl-rifabutin Please refer to the product
AUC ↓ 0.83 (0.74-0.92) information of the associated
Cmin ↓ 0.78 (0.70-0.87) boosted PI for the dose
Cmax ↓ 0.85 (0.72-1.00) adjustment of rifabutin to be
etravirine used.
AUC ↓ 0.63 (0.54-0.74)
Cmin ↓ 0.65 (0.56-0.74)
Cmax ↓ 0.63 (0.53-0.74)
BENZODIAZEPINES
Diazepam Not studied. Etravirine is expected to increase Alternatives to diazepam
plasma concentrations of diazepam. should be considered.
CORTICOSTEROIDS
Dexamethasone Not studied. Dexamethasone is expected to Systemic dexamethasone
(systemic) decrease plasma concentrations of etravirine should be used with caution
or alternatives should be
considered, particularly for
chronic use.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) rifabutin (HOS-086262) diazepam (HOS-085904) dexamethasone (HOS-084535) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage 7e0fe54c45d58654b9841db8a2c7e820382e98227be81a55de584c6f746bd26a · Zeichen 20177–24856 im Abschnitt
Gegenanzeigen · Eurartesim
Eurartesim 160 mg/20 mg film-coated tablets. · Abschnitt 4.3 · PDF-Seite 4
HOS-123010 · Präparat HOS-095623
- Recent treatment with medicinal products known to prolong the QTc interval that may still be
circulating at the time that Eurartesim is commenced (e.g. mefloquine, halofantrine,
lumefantrine, chloroquine, quinine and other antimalarial medicinal products) taking into
account their elimination half-life.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) halofantrine (HOS-085606) quinine (HOS-086616) mefloquine (HOS-113850) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage 0d59e0b0062764945cd6415e9f68e124be9691fba1debf3fc4076fae28b40fa4 · Zeichen 1909–2237 im Abschnitt
Gegenanzeigen · Eurartesim
Eurartesim 320 mg/40 mg film-coated tablets. · Abschnitt 4.3 · PDF-Seite 19
HOS-123064 · Präparat HOS-095623
- Recent treatment with medicinal products known to prolong the QTc interval that may still be
circulating at the time that Eurartesim is commenced (e.g. mefloquine, halofantrine,
lumefantrine, chloroquine, quinine and other antimalarial medicinal products) taking into
account their elimination half-life.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) halofantrine (HOS-085606) quinine (HOS-086616) mefloquine (HOS-113850) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-04T13:58:00Z · SHA-256 dabfe6fde6102b83217e8e60df06f7976dca1a5f1a6c99e5db65545ad780075f · Passage 0d59e0b0062764945cd6415e9f68e124be9691fba1debf3fc4076fae28b40fa4 · Zeichen 1895–2223 im Abschnitt
Wechselwirkungen · Signifor
Signifor 0.3 mg solution for injection Signifor 0.6 mg solution for injection Signifor 0.9 mg solution for injection · Abschnitt 4.5 · PDF-Seite 6
HOS-213401 · Präparat HOS-155106
Medicinal products that prolong the QT interval
Pasireotide should be used with caution in patients who are concomitantly receiving medicinal
products that prolong the QT interval, such as class Ia antiarrhythmics (e.g. quinidine, procainamide,
disopyramide), class III antiarrhythmics (e.g. amiodarone, dronedarone, sotalol, dofetilide, ibutilide),
certain antibacterials (intravenous erythromycin, pentamidine injection, clarithromycin, moxifloxacin),
certain antipsychotics (e.g. chlorpromazine, thioridazine, fluphenazine, pimozide, haloperidol,
tiapride, amisulpride, sertindole, methadone), certain antihistamines (e.g. terfenadine, astemizole,
mizolastine), antimalarials (e.g. chloroquine, halofantrine, lumefantrine), certain antifungals
(ketoconazole, except in shampoo) (see also section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) lumefantrine (HOS-114826) sotalol (HOS-085597) dronedarone (HOS-086144) methadone (HOS-086198) fluphenazine (HOS-213409) ketoconazole (HOS-084513) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) chlorpromazine (HOS-087796) thioridazine (HOS-086281) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) moxifloxacin (HOS-085604) astemizole (HOS-085608) pentamidine (HOS-085605) haloperidol (HOS-085602) amiodarone (HOS-085596) terfenadine (HOS-085607) tiapride (HOS-087799) chloroquine (HOS-109138) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 993e674cc3557753b51cbd078a1c6936fdf34c610462c4436f89d7e1f9025f1e · Zeichen 677–1481 im Abschnitt
Wechselwirkungen · Signifor
Signifor 10 mg powder and solvent for suspension for injection Signifor 20 mg powder and solvent for suspension for injection Signifor 30 mg powder and solvent for suspension for injection Signifor 40 mg powder and solvent for suspension for injection Signifor 60 mg powder and solvent for suspension for injection · Abschnitt 4.5 · PDF-Seite 21
HOS-213449 · Präparat HOS-155106
Medicinal products that prolong the QT interval
Pasireotide should be used with caution in patients who are concomitantly receiving medicinal
products that prolong the QT interval, such as class Ia antiarrhythmics (e.g. quinidine, procainamide,
disopyramide), class III antiarrhythmics (e.g. amiodarone, dronedarone, sotalol, dofetilide, ibutilide),
certain antibacterials (intravenous erythromycin, pentamidine injection, clarithromycin, moxifloxacin),
certain antipsychotics (e.g. chlorpromazine, thioridazine, fluphenazine, pimozide, haloperidol,
tiapride, amisulpride, sertindole, methadone), certain antihistamines (e.g. terfenadine, astemizole,
mizolastine), antimalarials (e.g. chloroquine, halofantrine, lumefantrine), certain antifungals
(ketoconazole, except in shampoo) (see also section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) lumefantrine (HOS-114826) sotalol (HOS-085597) dronedarone (HOS-086144) methadone (HOS-086198) fluphenazine (HOS-213409) ketoconazole (HOS-084513) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) chlorpromazine (HOS-087796) thioridazine (HOS-086281) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) moxifloxacin (HOS-085604) astemizole (HOS-085608) pentamidine (HOS-085605) haloperidol (HOS-085602) amiodarone (HOS-085596) terfenadine (HOS-085607) tiapride (HOS-087799) chloroquine (HOS-109138) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:26:00Z · SHA-256 8d39a4369995f88230d9c38d5acd5d8dc8ac03b6669b211c0130be10866c5ae6 · Passage 993e674cc3557753b51cbd078a1c6936fdf34c610462c4436f89d7e1f9025f1e · Zeichen 734–1538 im Abschnitt
Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-215290 · Präparat HOS-155418
Efavirenz:
AUC: ↑ 17% (↑ 6 to ↑ 29) **
Cmax: ↔**
*compared to 200 mg twice daily
alone
** compared to 600 mg once daily
alone
(Competitive inhibition of oxidative
metabolism)
Fluconazole/efavirenz No clinically significant No dose adjustment is necessary
(200 mg once daily/400 mg once pharmacokinetic interaction for either medicinal product.
daily)
Ketoconazole and other imidazole Interaction not studied No data are available to make a
antifungals dose recommendation.
Antimalarials
Artemether/lumefantrine/efaviren Artemether: Since decreased concentrations of
z AUC: ↓ 51% artemether, dihydroartemisinin, or
(20/120 mg tablet, 6 doses of 4 Cmax: ↓ 21% lumefantrine may result in a
decrease of antimalarial efficacy,
tablets each over 3 days/600mg Dihydroartemisinin:
caution is recommended when
once daily) AUC: ↓ 46% efavirenz and
Cmax: ↓ 38% artemether/lumefantrine tablets
Lumefantrine: are coadministered.
AUC: ↓ 21%
Cmax: ↔
Efavirenz:
AUC: ↓ 17%
Cmax: ↔
(CYP3A4 induction)
Atovaquone and proguanil Atovaquone: Concomitant administration of
hydrochloride/efavirenz AUC: ↓ 75% (↓ 62 to ↓ 84) atovaquone/proguanil with
(250/100 mg single dose/600 mg Cmax: ↓ 44% (↓ 20 to ↓ 61) efavirenz should be avoided.
once daily)
Proguanil:
AUC: ↓ 43% (↓ 7 to ↓ 65)
Cmax: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) atovaquone (HOS-086266) artemether (HOS-116383) ketoconazole (HOS-084513) imidazole (HOS-117862) proguanil (HOS-138707) fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage 5cd98510c464f750c7ae8b5b5719581ad750aac83e44de18e0a330ac52582331 · Zeichen 35927–38433 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-134497 · Präparat HOS-097580
15
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage or
colchicine and darunavir co- an interruption of colchicine
administered with low dose ritonavir treatment is recommended in
may increase the exposure to patients with normal renal or
colchicine. hepatic function if treatment with
(CYP3A and/ or P-gp inhibition) darunavir co-administered with low
dose ritonavir is required. For
patients with renal or hepatic
impairment colchicine with
darunavir co-administered with low
dose ritonavir is contraindicated
(see sections 4.3 and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of darunavir and
80/480 mg, 6 doses at 0, 8, artemether Cmin ↔ artemether/lumefantrine can be used
24, 36, 48, and 60 hours artemether Cmax ↓ 18% without dose adjustments; however,
dihydroartemisinin AUC ↓ 18% due to the increase in lumefantrine
dihydroartemisinin Cmin ↔ exposure, the combination should
dihydroartemisinin Cmax ↓ 18% be used with caution.
lumefantrine AUC ↑ 175%
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and
Rifapentine are strong CYP3A inducers and have darunavir with concomitant low
been shown to cause profound dose ritonavir is not recommended.
decreases in concentrations of other
protease inhibitors, which can result in The combination of rifampicin and
virological failure and resistance darunavir with concomitant low
development (CYP450 enzyme dose ritonavir is contraindicated
induction). During attempts to (see section 4.3).
overcome the decreased exposure by
increasing the dose of other protease
inhibitors with low dose ritonavir, a
high frequency of liver reactions was
seen with rifampicin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) protease (HOS-085623) colchicine (HOS-086147) rifapentine (HOS-116386) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 0ad9c8e97f03c4dbd0047b7a20b29278312211c101dacfc476c401ad8aa9174c · Zeichen 34084–37581 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58
HOS-134623 · Präparat HOS-097580
Clotrimazole Not studied. Concomitant systemic
use of clotrimazole and boosted
darunavir may increase plasma
concentrations of darunavir and/or
clotrimazole.
Darunavir AUC24h ↑ 33% (based on
population pharmacokinetic model)
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage or
colchicine and boosted darunavir an interruption of colchicine
may increase the exposure to treatment is recommended in patients
colchicine. with normal renal or hepatic function
(CYP3A and/ or P-gp inhibition) if treatment with boosted darunavir is
required. For patients with renal or
hepatic impairment colchicine with
boosted darunavir is contraindicated
(see sections 4.3 and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of boosted
80/480 mg, 6 doses at 0, 8, artemether Cmin ↔ darunavir and
24, 36, 48, and 60 hours artemether Cmax ↓ 18% artemether/lumefantrine can be used
dihydroartemisinin AUC ↓ 18% without dose adjustments; however,
dihydroartemisinin Cmin ↔ due to the increase in lumefantrine
dihydroartemisinin Cmax ↓ 18% exposure, the combination should be
lumefantrine AUC ↑ 175% used with caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and The combination of rifapentine and
Rifapentine rifampicin are strong CYP3A boosted darunavir is not
inducers and have been shown to recommended.
cause profound decreases in
concentrations of other protease The combination of rifampicin and
inhibitors, which can result in boosted darunavir is contraindicated
virological failure and resistance (see section 4.3).
development (CYP450 enzyme
induction). During attempts to
overcome the decreased exposure
by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) protease (HOS-085623) clotrimazole (HOS-090574) colchicine (HOS-086147) rifapentine (HOS-116386) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 64fdfa97cef778c7193c87ea0168964e1f464c278d0316c8ae901fe34d28a3c8 · Zeichen 40700–43992 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-138486 · Präparat HOS-098200
12
ANTIMALARIALS
Artemether/Lumefantrine Based on theoretical considerations Symtuza and
DRV/COBI is expected to increase artemether/lumefantrine can be
lumefantrine plasma used without dose adjustments;
concentrations. however, due to the increase in
(CYP3A inhibition) lumefantrine exposure, the
combination should be used with
caution.
ANTIMYCOBACTERIALS
Rifampicin Based on theoretical considerations The combination of rifampicin
rifampicin is expected to decrease and Symtuza is contraindicated
darunavir and/or cobicistat and/or (see section 4.3).
tenofovir alafenamide plasma
concentrations.
(CYP3A and/or P-gp induction)
Rifabutin Based on theoretical considerations Co-administration of Symtuza
Rifapentine these antimycobacterials are with rifabutin and rifapentine is
expected to decrease darunavir not recommended. If the
and/or cobicistat and/or tenofovir combination is needed, the
alafenamide plasma recommended dose of rifabutin is
concentrations. 150 mg 3 times per week on set
(CYP3A and/or P-gp induction) days (for example
Monday-Wednesday-Friday).
Increased monitoring for rifabutin
associated adverse reactions
including neutropenia and uveitis
is warranted due to an expected
increase in exposure to rifabutin.
Further dose reduction of
rifabutin has not been studied. It
should be kept in mind that the
twice weekly dose of 150 mg may
not provide an optimal exposure
to rifabutin thus leading to a risk
of rifamycin resistance and a
treatment failure. Consideration
should be given to official
guidance on the appropriate
treatment of tuberculosis in HIV
infected patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lumefantrine (HOS-114826) artemether (HOS-116383) rifabutin (HOS-086262) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 37b1a8ed5fbc959e0c62ff07b54b15ba0df2d2ba1c8eeefb033338da5eac50e7 · Zeichen 18477–21949 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-138704 · Präparat HOS-098240
13
result in loss of therapeutic effect of
Rifapentine/ Rilpivirine ↓ dolutegravir/rilpivirine (induction of CYP3A
Rilpivirine Not studied. Significant enzymes). Co-administration of
decreases in rilpivirine dolutegravir/rilpivirine with rifapentine is
plasma concentrations are contraindicated (see section 4.3).
expected.
Antimalarials
Artemether/ Dolutegravir The combination of dolutegravir/rilpivirine and
Lumefantrine/ (Not studied) artemether/lumefantrine should be used with
Dolutegravir caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) rifapentine (HOS-116386)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 96317d415fed2e0394941b468c93f424ca0fb4f22169acf08db88ee7cc266c64 · Zeichen 24813–25643 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-138705 · Präparat HOS-098240
Artemether/ Rilpivirine ↓
Lumefantrine/ Not studied. Decreased
Rilpivirine exposure of rilpivirine is
expected
(induction of CYP3A
enzymes).
Atovaquone/ Dolutegravir No dose adjustment is required.
Proguanil/ (Not studied)
Dolutegravir
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) atovaquone (HOS-086266) artemether (HOS-116383) proguanil (HOS-138707)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 8548bf884225c9d58d917431812e9fd8897a0549dd23ab845a914320fbeccddd · Zeichen 25645–26048 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.